| Project/Area Number |
14570154
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
YAZAWA Takuya Yokohama City University Graduate School of Medicine, Department of Pathology, Associate Professor, 大学院・医学研究科, 助教授 (50251054)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KITAMURA Hitoshi Yokohama City University Graduate School of Medicine, Department of Pathology, Professor, 大学院・医学研究科, 教授 (20094302)
伊藤 隆明 横浜市立大学, 医学部, 助教授 (70168392)
奥寺 康司 横浜市立大学, 医学部, 助手 (10326027)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2003: ¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 2002: ¥1,900,000 (Direct Cost: ¥1,900,000)
|
|---|
| Keywords | Class II Transactivator / Major Histocompatibility Complex / Cancer / Tumor Immunity / Tatタンパク |
|---|
| Research Abstract |
In the first year, we tried to establish the system to delivery the recombinant hCIITA molecules into cancer cells. We first used VP22 tag derived from HSV as a candidate of deliverers, the VP22 interfered the function of hCIITA. Thus, we next used Tat tag derived from HIV and obtained the facts that Tat-hCIITA has enough function to induce MHC antigens in cancer cells and purified recombinant Tat-hCIITA protein in the culture media move into cancer cells and could make MHC induce. However, it was impossible to get enough amounts of recombinant Tat-hCIITA protein, since the protein formed inclusion body in E.coli.
In the second year, we tried to establish the co-expression system of hCIITA and MHC haplotype-matched antigenicoligopeptides (Tb (k) and Tb (km) = I-A^k-haplotype matched oligopeptides, Tb (b) = I-A^b-haplotype matched oligopeptides) derived from Mycobacterium tuberculosis alpha antigen. We constructed the expression vectors, pZeo-hCIITA-HA-furin-Tb (k) -His, pZeo-hCIITA-HA furin-Tb (km) -His, and pZeo-hCIITA-HA-furin-Tb (b)-His and transfected into he C1300 (mouse neuroblastoma cell line derived from A/J mouse (I-A^k haplotype), MM102 (mouse breast cancer cell line derived from C3H/HeN mouse (I-A^k haptotype), and Lewis (mouse lung cancer cell line derived from C57BL/6 mouse (I-A^b haplotype). We have established stably hCIITA-and Tb (b)-coexpressed transfectants (Lewis-pZeo-hCIITA-HA-furin-Tb(b)-His and MM102-pZeo-hCIITA-HA furin-Tb (b)-His) and got the evidence that Lewis-pZeo-hCIITA-HA furin-Tb (b)-His generates well tumor immunity against tumor-laden hosts.
|
